Perhaps the most consistent findings in ALS biomarkers involve biomarkers of neurodegeneration, specifically NfL, which may be used to complement clinical diagnosis given its high sensitivity and the availability of its detection techniques. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.